Concepts (166)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Nose Diseases | 2 | 2021 | 8 | 0.720 |
Why?
|
| Odontogenic Tumors | 2 | 2018 | 9 | 0.670 |
Why?
|
| Mouth Diseases | 2 | 2015 | 38 | 0.600 |
Why?
|
| Head and Neck Neoplasms | 3 | 2021 | 561 | 0.550 |
Why?
|
| Salivary Gland Diseases | 1 | 2015 | 3 | 0.530 |
Why?
|
| Mucocele | 2 | 2010 | 20 | 0.440 |
Why?
|
| Diagnosis, Differential | 2 | 2015 | 1140 | 0.430 |
Why?
|
| Lip Diseases | 2 | 2010 | 8 | 0.380 |
Why?
|
| Lip | 1 | 2009 | 12 | 0.350 |
Why?
|
| Mouth Neoplasms | 3 | 2021 | 206 | 0.350 |
Why?
|
| Datasets as Topic | 2 | 2018 | 52 | 0.330 |
Why?
|
| Carcinoma, Squamous Cell | 3 | 2021 | 624 | 0.310 |
Why?
|
| Thyroid Neoplasms | 3 | 2016 | 68 | 0.260 |
Why?
|
| Practice Guidelines as Topic | 2 | 2018 | 772 | 0.230 |
Why?
|
| Neoplasm Recurrence, Local | 2 | 2021 | 444 | 0.220 |
Why?
|
| Carcinoma | 2 | 2018 | 215 | 0.210 |
Why?
|
| Mouth Mucosa | 3 | 2011 | 51 | 0.210 |
Why?
|
| Pathology, Clinical | 2 | 2018 | 16 | 0.200 |
Why?
|
| Skull Base Neoplasms | 1 | 2001 | 13 | 0.200 |
Why?
|
| Nasal Cartilages | 1 | 2021 | 2 | 0.200 |
Why?
|
| Hamartoma | 1 | 2021 | 24 | 0.190 |
Why?
|
| Programmed Cell Death 1 Receptor | 1 | 2021 | 87 | 0.190 |
Why?
|
| Mesoderm | 1 | 2021 | 231 | 0.180 |
Why?
|
| Humans | 25 | 2021 | 68549 | 0.140 |
Why?
|
| Peritoneal Neoplasms | 1 | 2017 | 23 | 0.140 |
Why?
|
| Mesothelioma | 1 | 2017 | 21 | 0.140 |
Why?
|
| Biomarkers, Tumor | 2 | 2016 | 508 | 0.130 |
Why?
|
| Paranasal Sinuses | 1 | 2015 | 165 | 0.110 |
Why?
|
| Metaplasia | 2 | 2010 | 27 | 0.110 |
Why?
|
| Maxillary Neoplasms | 1 | 2012 | 12 | 0.110 |
Why?
|
| Rhabdomyosarcoma | 1 | 2012 | 36 | 0.110 |
Why?
|
| Lip Neoplasms | 1 | 2011 | 12 | 0.100 |
Why?
|
| Fibroma | 1 | 2011 | 20 | 0.100 |
Why?
|
| Vascular Neoplasms | 1 | 2011 | 15 | 0.100 |
Why?
|
| Fasciitis | 1 | 2011 | 30 | 0.100 |
Why?
|
| Electrosurgery | 1 | 2010 | 15 | 0.090 |
Why?
|
| Sciatic Nerve | 1 | 2010 | 26 | 0.090 |
Why?
|
| Parotid Gland | 1 | 2010 | 33 | 0.090 |
Why?
|
| Facial Paralysis | 1 | 2010 | 25 | 0.090 |
Why?
|
| Plasminogen | 1 | 2008 | 28 | 0.080 |
Why?
|
| Gingival Diseases | 1 | 2008 | 22 | 0.080 |
Why?
|
| Genital Diseases, Female | 1 | 2008 | 23 | 0.080 |
Why?
|
| Peritoneum | 1 | 2008 | 27 | 0.080 |
Why?
|
| Child | 4 | 2021 | 6401 | 0.080 |
Why?
|
| Paranasal Sinus Diseases | 1 | 2008 | 30 | 0.080 |
Why?
|
| Male | 9 | 2021 | 37283 | 0.070 |
Why?
|
| Female | 12 | 2021 | 38021 | 0.070 |
Why?
|
| Neck Dissection | 2 | 2021 | 55 | 0.070 |
Why?
|
| Carcinoma, Merkel Cell | 1 | 2006 | 12 | 0.070 |
Why?
|
| Adenocarcinoma, Papillary | 1 | 2005 | 12 | 0.060 |
Why?
|
| Infertility, Female | 1 | 2004 | 25 | 0.060 |
Why?
|
| Thyroidectomy | 1 | 2005 | 31 | 0.060 |
Why?
|
| Adenocarcinoma, Follicular | 1 | 2005 | 13 | 0.060 |
Why?
|
| Aged | 7 | 2021 | 14842 | 0.060 |
Why?
|
| Endometrium | 1 | 2004 | 31 | 0.060 |
Why?
|
| Neoplasm Invasiveness | 1 | 2006 | 369 | 0.060 |
Why?
|
| Fertility | 1 | 2004 | 60 | 0.060 |
Why?
|
| Research Design | 2 | 2018 | 729 | 0.060 |
Why?
|
| Survival Analysis | 2 | 2021 | 714 | 0.060 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2004 | 129 | 0.060 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 125 | 0.060 |
Why?
|
| Salivary Gland Neoplasms | 1 | 2004 | 40 | 0.060 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2003 | 14 | 0.060 |
Why?
|
| Neoplasm Staging | 2 | 2021 | 799 | 0.060 |
Why?
|
| Prognosis | 3 | 2021 | 2093 | 0.060 |
Why?
|
| Prostaglandin-Endoperoxide Synthases | 1 | 2003 | 73 | 0.050 |
Why?
|
| Surgical Procedures, Operative | 1 | 2004 | 124 | 0.050 |
Why?
|
| Endometrial Neoplasms | 1 | 2003 | 69 | 0.050 |
Why?
|
| Middle Aged | 7 | 2021 | 21119 | 0.050 |
Why?
|
| Neck | 1 | 2002 | 62 | 0.050 |
Why?
|
| Tympanic Membrane | 1 | 2002 | 25 | 0.050 |
Why?
|
| Ear Canal | 1 | 2002 | 24 | 0.050 |
Why?
|
| Mastoid | 1 | 2002 | 20 | 0.050 |
Why?
|
| Retrospective Studies | 5 | 2021 | 7268 | 0.050 |
Why?
|
| Adult | 9 | 2017 | 21379 | 0.050 |
Why?
|
| Angiofibroma | 1 | 2001 | 4 | 0.050 |
Why?
|
| Chordoma | 1 | 2001 | 9 | 0.050 |
Why?
|
| Chondrosarcoma | 1 | 2001 | 7 | 0.050 |
Why?
|
| Esthesioneuroblastoma, Olfactory | 1 | 2001 | 10 | 0.050 |
Why?
|
| Paraganglioma | 1 | 2001 | 8 | 0.050 |
Why?
|
| Isoenzymes | 1 | 2003 | 308 | 0.050 |
Why?
|
| Carcinoma, Adenoid Cystic | 1 | 2001 | 12 | 0.050 |
Why?
|
| Hyalin | 2 | 2012 | 8 | 0.050 |
Why?
|
| Inflammation | 1 | 2008 | 1030 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2006 | 375 | 0.050 |
Why?
|
| Skull Base | 1 | 2002 | 72 | 0.050 |
Why?
|
| Pituitary Neoplasms | 1 | 2001 | 52 | 0.050 |
Why?
|
| Nerve Sheath Neoplasms | 1 | 2001 | 33 | 0.050 |
Why?
|
| Neoadjuvant Therapy | 1 | 2021 | 104 | 0.050 |
Why?
|
| Meningeal Neoplasms | 1 | 2001 | 42 | 0.050 |
Why?
|
| Ovarian Neoplasms | 1 | 2003 | 267 | 0.050 |
Why?
|
| Margins of Excision | 1 | 2021 | 15 | 0.050 |
Why?
|
| Calcinosis | 1 | 2002 | 241 | 0.050 |
Why?
|
| Antineoplastic Agents, Immunological | 1 | 2021 | 66 | 0.050 |
Why?
|
| Meningioma | 1 | 2001 | 54 | 0.050 |
Why?
|
| Combined Modality Therapy | 3 | 2012 | 951 | 0.050 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2021 | 33 | 0.050 |
Why?
|
| Incidental Findings | 1 | 2021 | 42 | 0.050 |
Why?
|
| Uterine Cervical Neoplasms | 1 | 2003 | 285 | 0.050 |
Why?
|
| Adenocarcinoma | 1 | 2003 | 475 | 0.040 |
Why?
|
| Cohort Studies | 2 | 2021 | 2356 | 0.040 |
Why?
|
| Collagen | 1 | 2002 | 636 | 0.040 |
Why?
|
| Aged, 80 and over | 4 | 2010 | 4843 | 0.040 |
Why?
|
| Survival Rate | 1 | 2021 | 1055 | 0.040 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2021 | 756 | 0.040 |
Why?
|
| DNA Mutational Analysis | 1 | 2016 | 159 | 0.030 |
Why?
|
| Thyroid Gland | 1 | 2016 | 67 | 0.030 |
Why?
|
| Treatment Outcome | 2 | 2021 | 7028 | 0.030 |
Why?
|
| Myogenin | 1 | 2012 | 9 | 0.030 |
Why?
|
| Desmin | 1 | 2012 | 13 | 0.030 |
Why?
|
| Sclerosis | 1 | 2012 | 32 | 0.030 |
Why?
|
| Biopsy, Fine-Needle | 1 | 2012 | 76 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2012 | 164 | 0.030 |
Why?
|
| Sarcoma | 1 | 2012 | 70 | 0.030 |
Why?
|
| Bone Neoplasms | 1 | 2012 | 100 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2021 | 2324 | 0.020 |
Why?
|
| Cheek | 1 | 2010 | 11 | 0.020 |
Why?
|
| Mouth Floor | 1 | 2010 | 9 | 0.020 |
Why?
|
| Palate | 1 | 2010 | 14 | 0.020 |
Why?
|
| Electrocoagulation | 1 | 2010 | 34 | 0.020 |
Why?
|
| Tongue Diseases | 1 | 2010 | 14 | 0.020 |
Why?
|
| Color | 1 | 2010 | 50 | 0.020 |
Why?
|
| Rupture | 1 | 2010 | 29 | 0.020 |
Why?
|
| Mouth | 1 | 2010 | 64 | 0.020 |
Why?
|
| Parotid Neoplasms | 1 | 2010 | 49 | 0.020 |
Why?
|
| Single-Blind Method | 1 | 2010 | 249 | 0.020 |
Why?
|
| Mast Cells | 1 | 2010 | 113 | 0.020 |
Why?
|
| Young Adult | 2 | 2011 | 5710 | 0.020 |
Why?
|
| Random Allocation | 1 | 2010 | 442 | 0.020 |
Why?
|
| United States | 1 | 2021 | 7338 | 0.020 |
Why?
|
| Sex Factors | 1 | 2010 | 1265 | 0.020 |
Why?
|
| Probability | 1 | 2006 | 244 | 0.020 |
Why?
|
| Biopsy, Needle | 1 | 2006 | 191 | 0.020 |
Why?
|
| Rats, Sprague-Dawley | 1 | 2010 | 2083 | 0.020 |
Why?
|
| Age Factors | 1 | 2010 | 1860 | 0.020 |
Why?
|
| Cause of Death | 1 | 2006 | 241 | 0.020 |
Why?
|
| Thyroglobulin | 1 | 2005 | 17 | 0.020 |
Why?
|
| Luteal Phase | 1 | 2004 | 25 | 0.020 |
Why?
|
| Thyroid Hormones | 1 | 2005 | 31 | 0.020 |
Why?
|
| Life Expectancy | 1 | 2005 | 51 | 0.020 |
Why?
|
| Radionuclide Imaging | 1 | 2005 | 166 | 0.020 |
Why?
|
| Adolescent | 2 | 2010 | 8904 | 0.010 |
Why?
|
| Observer Variation | 1 | 2004 | 330 | 0.010 |
Why?
|
| Infant | 1 | 2010 | 2891 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2012 | 1172 | 0.010 |
Why?
|
| South Carolina | 1 | 2010 | 2752 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2010 | 3187 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 1174 | 0.010 |
Why?
|
| Oral Surgical Procedures | 1 | 2003 | 15 | 0.010 |
Why?
|
| Prospective Studies | 1 | 2010 | 3703 | 0.010 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2003 | 282 | 0.010 |
Why?
|
| Microsurgery | 1 | 2003 | 46 | 0.010 |
Why?
|
| Registries | 1 | 2006 | 730 | 0.010 |
Why?
|
| Biopsy | 1 | 2004 | 539 | 0.010 |
Why?
|
| Cyclooxygenase 2 | 1 | 2003 | 160 | 0.010 |
Why?
|
| Rats | 1 | 2010 | 5300 | 0.010 |
Why?
|
| Epithelium | 1 | 2002 | 172 | 0.010 |
Why?
|
| Life Style | 1 | 2003 | 338 | 0.010 |
Why?
|
| Neoplasms | 1 | 2011 | 1664 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 2004 | 0.010 |
Why?
|
| Diet | 1 | 2003 | 514 | 0.010 |
Why?
|
| Clinical Trials as Topic | 1 | 2003 | 848 | 0.010 |
Why?
|
| Membrane Proteins | 1 | 2003 | 617 | 0.010 |
Why?
|
| Time Factors | 1 | 2004 | 4655 | 0.010 |
Why?
|
| Risk Factors | 1 | 2005 | 5720 | 0.010 |
Why?
|
| Animals | 1 | 2010 | 20880 | 0.010 |
Why?
|